Management of Antidepressant-Induced Sexual Dysfunction: A Literature Review

Area of Science:

• Psychiatry
• Pharmacology
• Sexual Medicine

Background:

• Selective serotonin reuptake inhibitors (SSRIs) are primary treatments for depression and anxiety disorders.
• Sexual side effects, including decreased libido and orgasm dysfunction, are common adverse effects of SSRIs.
• Antidepressant-induced sexual dysfunction (AISD) can negatively impact treatment adherence and quality of life.

Purpose of the Study:

• To review the effectiveness of switching antidepressant therapy or adding adjunctive treatments for managing AISD.
• To explore potential pharmacological and herbal interventions for SSRI-induced sexual dysfunction.

Main Methods:

• A narrative review of English-language articles from PubMed (1996-2023) was conducted.
• Searched for studies discussing antidepressant-induced sexual dysfunction and its management.
• Selected articles focused on switching antidepressants or adjunctive therapies.

Main Results:

• Switching to antidepressants like mirtazapine, nefazodone, or vortioxetine may benefit some patients.
• Adjunctive bupropion and saffron (Crocus sativus) show promise in managing AISD.
• Evidence for vilazodone and Ginkgo biloba is conflicting; more research is needed for other adjunctive treatments.

Conclusions:

• Switching or augmenting antidepressant therapy can be effective strategies for managing AISD.
• Bupropion and saffron are potential options, but further research is required for many interventions.
• More studies are needed to understand AISD pathophysiology and develop broader management options.